- Leading the Product Management team to design, lead, operate, & execute the product portfolio and define a seamless clinical experience for early cancer detection blood tests- Serving as a thought partner on the Product Development and Commercial leadership teams- Defined a lung cancer screening test, which was a key catalyst of Freenome’s $254M funding round in Feb. 2024- Recognized as "High Potential" by the Product and Commercial organizations

- Delivered on the strategic plan and commercial vision of the Precision Oncology Business Unit by partnering with business unit leadership and enabling function teams- Facilitated efficient decision making by organizing and prioritizing critical issues and required information- Expanded role included leadership of the Product Management and Commercial Analytics teams of 12 people

- Led a 6-member Portfolio and Risk Management team to focus the organization's resources on solutions that drive the most value- Drove transformation of portfolio management for Molecular Labs (>$500 million budget)- Facilitated the portfolio committee and member of the leadership team for Molecular Labs

- Developed and operationalized the strategy & long-term roadmap for Roche Molecular Solutions (included Molecular Diagnostics, Tissue Diagnostics, & Sequencing business units)- Led teams focused on initiatives that contributed to growth and operational excellence; select initiatives included harmonization of product development processes, evaluation & implementation of portfolio decisions, and improvement of overall customer experience

- Led 2 cross-functional teams responsible for driving product development from project initiation through post-launch review for 5 assays on the cobas Liat System- Achieved feasibility to CE marking in less than 16 months, resulting in accomplishment of an acquisition milestone- Nominated to lead or participate as a key contributor in multiple ad hoc projects, including Roche’s Point of Care strategy for growth

- Managed a cross-functional team to integrate IQuum into Roche- Developed and executed the acquisition of IQuum for $450M- Refined and developed Roche’s Molecular Diagnostics strategy- Received Outstanding Performance rating, awarded Key Contributor Long Term Incentive (one of 600 out of over 90,000 employees), and promoted from Manager to Senior Manager

- Led modules of project work and drove insights; select projects included high value oncology diagnostics strategy, companion diagnostics strategy, landscape in next generation sequencing, and mass spectrometry for clinical diagnostics- Received highest performance rating (top 20%) for 2 consecutive 6-month review periods and promoted after 12 months